New injection CBL-514 shown to reduce visceral fat in human trials

Key Points:

• Early human trials of the experimental injection CBL-514 have demonstrated its potential to reduce harmful visceral fat, which is linked to metabolic issues and increased risk of type 2 diabetes and heart failure.
• The trials, led by researchers from the University of Alabama and Caliway Biopharmaceuticals, showed a 12.01% reduction in visceral fat volume in treated participants, compared to a 5.68% increase in those given a placebo.
• CBL-514 works by selectively inducing apoptosis in fat cells without harming surrounding tissues, and treatment involved injections into the lower abdomen every three weeks for up to 12 weeks.
• Beyond cosmetic benefits like a flatter stomach, the injection also contributes to weight loss, improved blood pressure, and better cholesterol levels, which are critical for overall health.
• Unlike liposuction, which cannot remove visceral fat, CBL-514 targets this dangerous fat type, potentially reducing associated health risks.